CardiomyopathiesCMR-MN-31PNCT07912086
31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum
An observational study of Cardiomyopathies and Heart Failure, run by Chinese Academy of Medical Sciences, Fuwai Hospital at 1 site in China.
Trial summary
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiomyopathies, Heart Failure
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2025to 1 Sep 2035
- How long will I take part?
- 36 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.
Who may be able to join
- Age >= 18 years
- Healthy volunteers, OR
- Clinical diagnosis of cardiac disease, including non-ischemic cardiomyopathy (hypertrophic, amyloid, or inflammatory), ischemic cardiomyopathy, hypertensive heart disease, or valvular heart disease, OR
- Inherited metabolic cardiomyopathies
- Able to undergo CMR examination and provide written informed consent
Who cannot join
- Any contraindication to CMR examination
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital
Beijing, 100037
Lu Minjie, MD，PHD, +86 68314466, coolkan@163.com
About this study
Official title: Myocardial Energetic Phenotyping and Prognostic Value Across the Cardiac Disease Spectrum: A 31P Magnetic Resonance Spectroscopy Study
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS).
And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.
By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.
- Conditions
- Cardiomyopathies, Heart Failure
- Keywords
- cardiomyopathy, 31P-magnetic resonance spectroscopy, myocardial metabolism, Heart Failure, cardiac magnetic resonance
- Medical subject headings
- Cardiomyopathies, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy controls | Volunteers without cardiovascular disease undergoing the same CMR and 31P-MRS protocol to establish reference values. | |
| Heart failure | Patients primarily enrolled with a clinical diagnosis of heart failure, comprehensively encompassing preserved (HFpEF) and reduced ejection fraction (HFrEF) phenotypes. | |
| Non-ischemic cardiomyopathy | Patients primarily diagnosed with non-ischemic etiologies, prominently including hypertrophic cardiomyopathy (HCM), as well as amyloid, or inflammatory cardiomyopathies. | |
| Ischemic cardiomyopathy | Patients with cardiomyopathy primarily attributable to coronary artery disease. | |
| Other structural heart disease | Patients with hypertensive heart disease or valvular heart disease. | |
| Inherited cardiomyopathy | Patients with cardiomyopathy attributable to a primary gene mutation related with myocardial energy metabolism. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Myocardial phosphocreatine to ATP ratio (PCr/ATP)
Myocardial PCr/ATP measured by 31P magnetic resonance spectroscopy
Measured: At baseline CMR examination
Secondary outcomes (1)
Composite Cardiovascular and Heart Failure Events
The composite clinical endpoint includes cardiovascular mortality, heart failure-related events (including hospitalization for heart failure, heart transplantation, or implantation of a mechanical circulatory support device), and documented life-threatening arrhythmias. The components of this composite outcome will be specified according to the specific cardiac disease cohort being evaluated.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start1 Aug 2025
- Primary completion1 Sep 2030 (estimated)
- Study completion1 Sep 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CardiomyopathiesStudies of the same condition, open and under way.
- More trials run by Chinese Academy of Medical Sciences, Fuwai HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 36 Months
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Minjie Lu, Chinese Academy of Medical Sciences, Fuwai Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07912086
- Sponsor's protocol ID
- CMR-MN-31P
- Acronym
- CMR-MN-31P
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myocardial Energetic Phenotyping and Prognostic Value Across the Cardiac Disease Spectrum: A 31P Magnetic Resonance Spectroscopy Study
- ClinicalTrials.gov ID
- NCT07912086
- Acronym / sponsor ID
- CMR-MN-31P / CMR-MN-31P
- Conditions
- Cardiomyopathies, Heart Failure
- Keywords
- cardiomyopathy, 31P-magnetic resonance spectroscopy, myocardial metabolism, Heart Failure, cardiac magnetic resonance
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 1 Sep 2030 (estimated)
- Study completion
- 1 Sep 2035 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS).
And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.
By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 36 Months
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Healthy controls | – | –Volunteers without cardiovascular disease undergoing the same CMR and 31P-MRS protocol to establish reference values. |
| Heart failure | – | –Patients primarily enrolled with a clinical diagnosis of heart failure, comprehensively encompassing preserved (HFpEF) and reduced ejection fraction (HFrEF) phenotypes. |
| Non-ischemic cardiomyopathy | – | –Patients primarily diagnosed with non-ischemic etiologies, prominently including hypertrophic cardiomyopathy (HCM), as well as amyloid, or inflammatory cardiomyopathies. |
| Ischemic cardiomyopathy | – | –Patients with cardiomyopathy primarily attributable to coronary artery disease. |
| Other structural heart disease | – | –Patients with hypertensive heart disease or valvular heart disease. |
| Inherited cardiomyopathy | – | –Patients with cardiomyopathy attributable to a primary gene mutation related with myocardial energy metabolism. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies.
Key inclusion criteria (5 listed)
- Age >= 18 years
- Healthy volunteers, OR
- Clinical diagnosis of cardiac disease, including non-ischemic cardiomyopathy (hypertrophic, amyloid, or inflammatory), ischemic cardiomyopathy, hypertensive heart disease, or valvular heart disease, OR
- Inherited metabolic cardiomyopathies
- Able to undergo CMR examination and provide written informed consent
Key exclusion criteria (1 listed)
- Any contraindication to CMR examination
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Myocardial phosphocreatine to ATP ratio (PCr/ATP)
Time frame: At baseline CMR examination
Myocardial PCr/ATP measured by 31P magnetic resonance spectroscopy
1 secondary outcome
Composite Cardiovascular and Heart Failure Events
Time frame: Up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
Related trials for Cardiomyopathies
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital
Beijing, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiomyopathies and Heart Failure, run by Chinese Academy of Medical Sciences, Fuwai Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Myocardial phosphocreatine to ATP ratio (PCr/ATP) (time frame: At baseline CMR examination). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.